BPC-157

BPC-157 is a synthetic pentadecapeptide — a chain of 15 amino acids — derived from a protective protein naturally found in human gastric juice. It is one of the most extensively studied research peptides for its remarkable regenerative effects on tendons, ligaments, muscles, bones, and the gut lining. Unlike most peptides, BPC-157 retains significant activity when administered orally, making it uniquely versatile for gastrointestinal research applications.

BPC-157 exerts its effects through several interconnected molecular pathways. It upregulates vascular endothelial growth factor (VEGF) and promotes angiogenesis — the formation of new blood vessels — which dramatically accelerates oxygen and nutrient delivery to damaged tissue. It activates the nitric oxide (NO) system, modulating vascular tone and reducing ischemia in injured areas. BPC-157 also interacts with the dopaminergic and serotonergic systems, explaining observed effects on mood, stress response, and pain modulation. At the cellular level, it upregulates growth hormone receptors in tendon fibroblasts, accelerating collagen synthesis and extracellular matrix remodeling. Additionally, it suppresses NF-κB inflammatory signaling, blunting the destructive phase of inflammation without fully eliminating the beneficial acute phase. Its gut-protective effects arise from its ability to repair intestinal epithelial tight junctions, making it highly researched for leaky gut, IBD, and NSAID-induced ulceration.

BPC-157 has been studied in over 100 preclinical rodent studies across multiple research groups, primarily at the University of Zagreb under Dr. Sikiric. Consistent findings include accelerated healing of tendons (Achilles, patellar), ligaments (ACL), muscles, and intestinal tissue. Fistula healing, NSAID-induced gut damage reversal, and bone fracture acceleration have been replicated across independent labs. No formal randomized human clinical trials (RCTs) have been published as of 2024, though Phase II clinical trials for IBD have been initiated. It is on the WADA prohibited list monitoring program. The lack of LD50 in animal models suggests an exceptionally wide therapeutic index.

Injury Recovery Protocol: 400 mcg twice daily (morning and pre-bed) subcutaneously near the injury site for 6–8 weeks. Gut Healing Protocol: 250–500 mcg orally on an empty stomach, 30 minutes before meals, for 4–8 weeks. General Wellness Stack: often combined with TB-500 at 2–5 mg twice weekly for synergistic systemic healing. For joint support, some research protocols combine BPC-157 (300 mcg/day SC) with GHK-Cu (200 mcg/day SC) for enhanced collagen and connective tissue support.

BPC-157 has an exceptionally wide safety profile in animal research with no identified lethal dose (LD1 not established). The most commonly reported effects in human research and anecdotal use include mild nausea, particularly with oral dosing, which typically resolves within the first week. Some users report temporary dizziness or lightheadedness immediately post-injection, likely related to its transient vasodilatory effects. Vivid dreams or changes in sleep quality are occasionally noted, possibly due to its interaction with dopamine pathways. Mild injection site redness or irritation can occur with subcutaneous administration. Importantly, BPC-157 does not meaningfully suppress the hypothalamic-pituitary axis, making it safe for concurrent use with other hormonal research protocols.

Store lyophilized (freeze-dried) BPC-157 powder at 2–8°C (refrigerator) away from light and moisture. Lyophilized powder is stable for 12–24 months under proper refrigeration. Once reconstituted with bacteriostatic water (BAC water), store the solution in the refrigerator and use within 28–30 days. Do not freeze reconstituted peptide solution. Keep away from heat sources and direct sunlight. Use standard insulin syringes (U-100) for dosing reconstituted solutions.